COMPUS Reports
August 10, 2010
COMPUS Reports
August 4, 2010
COMPUS Reports
August 4, 2010
COMPUS Reports
March 29, 2010
View Tool “Using Evidence in the Real World” is a didactic presentation that provides a basic overview of evidence-based decision making, using CADTH's work on self-monitoring of blood glucose and insulin analogues as examples. ...
COMPUS Reports
March 29, 2010
View Tool The Guide to Starting and Adjusting Insulin for Type 2 Diabetes is a fold out information card providing health care professionals with guidance on how and when to start insulin....
COMPUS Reports
March 12, 2010
COMPUS Reports
December 8, 2009
The Canadian Agency for Drugs and Technologies in Health (CADTH) ― through its Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) — has released a series of Optimal Therapy Reports on the self-monitoring of blood glucose (SMBG), together with recommendations and int...
COMPUS Reports
November 12, 2009
COMPUS Reports
November 12, 2009
COMPUS Reports
July 28, 2009
COMPUS Reports
July 28, 2009
COMPUS Reports
May 15, 2009
COMPUS Reports
May 15, 2009
COMPUS Reports
March 31, 2009
COMPUS Reports
March 31, 2009
COMPUS Reports
March 31, 2009
COMPUS Reports
March 31, 2009
COMPUS Reports
March 27, 2009
COMPUS Reports
March 9, 2009
COMPUS Reports
March 9, 2009
COMPUS Reports
January 20, 2009
This report is prepared by the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS), a service of the Canadian Agency for Drugs and Technologies in Health (CADTH). This report is based on the comparison of evidence-based recommendations related to the prescribing and use of insul...
COMPUS Reports
January 20, 2009
This report is based on comprehensive meta-analyses — Long-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes, Update of CADTH Technology Report No. 92; and Rapid-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of ...
COMPUS Reports
October 15, 2008
This report has been prepared by the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS), a service of the Canadian Agency for Drugs and Technologies in Health (CADTH). It contains a comprehensive review of existing public literature, studies, materials, and other information an...
COMPUS Reports
May 15, 2008
The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) is producing a collection of intervention tools to disseminate its key messages on proton pump inhibitors (PPIs). The following tools are being developed in collaboration with experts in continuing professional development...
COMPUS Reports
April 15, 2008
COMPUS Reports
March 25, 2008
Most studies of the long-acting insulin analogues were of poor quality and were not designed to measure differences in clinically important outcomes. There is no evidence that IGlar offers benefit over NPH insulin in children with type 1 DM, although IDet may have benefits in terms of reduced noc...
COMPUS Reports
March 25, 2008
The objective of this economic assessment was to determine the cost-effectiveness of using IAs in the management of T1DM and T2DM, compared to HIs, in Canada. The results of this analysis may assist those who are responsible for making informed judgments on the reimbursement and prescribing of IAs f...
COMPUS Reports
March 1, 2008
To identify and promote the implementation of evidence-based and cost-effective optimal therapy in the prescribing and use of long and rapid-acting insulin analogues, COMPUS followed the process outlined in the flow chart to the right. This report represents Current Utilization Analysis step....
COMPUS Reports
January 15, 2008
The bulk of the available evidence on rapid-acting insulin analogues for both type 1 and type 2 diabetes consists of short- to medium-term comparisons with HI in terms of A1c and hypoglycemia. Most studies were of poor methodological quality. Based on the available evidence, the benefit of rapid...
COMPUS Reports
January 15, 2008
The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) has applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to its work. The GRADE approach was developed to assist recommendation-making groups in making judgments about the qualit...
COMPUS Reports
January 1, 2008
For less than a decade, insulin analogues have been available to be used in combination with, or as replacements for, human insulins, providing new treatment options with type 1 or type 2 diabetes. Several recent reviews of randomized controlled trials comparing regular human and analogue insuli...
COMPUS Reports
September 1, 2007
The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) self-audit tool is intended as a template and may be customized to suit the requirements of the distributor (provincial jurisdictions or continuing education providers, for example). The information collected enables the di...
COMPUS Reports
April 15, 2007
The academic detailing upskilling document on proton pump inhibitors is intended as a companion document to the Canadian Agency for Drugs and Technologies in Health’s (CADTH’s) Scientific Report entitled, Evidence for PPI Use in Gastroesophageal Reflux Disease, Dyspepsia and Peptic Ul...
COMPUS Reports
April 15, 2007
Optimal Therapy Newsletter: Proton Pump Inhibitors...
COMPUS Reports
April 15, 2007
OBJECTIVE COMPARATIVE DRUG INFORMATION & EDUCATION RxFiles Academic Detailing Program Saskatchewan’s Academic Detailing Program...
COMPUS Reports
April 1, 2007
The clinical and economic evidence for the treatment of common GI ailments (i.e., uninvestigated GERD, uninvestigated dyspepsia, and NSAID ulcer = prophylaxis) in the general practice setting suggests that PPIs (at a price equal to or less than $1.25 per day) may be cost-effective depending on thewi...
COMPUS Reports
April 1, 2007
Presentation for Pharmacists...
COMPUS Reports
April 1, 2007
COMPUS Reports
March 15, 2007
This Executive Summary is based on a comprehensive Scientific Report (Optimal Therapy Report – COMPUS: Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease: scientific report) and economic report on the topic, prepared by the Canadian Optimal Medicatio...
COMPUS Reports
March 15, 2007
1. ISSUE The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) was tasked by the federal, provincial, and territorial ministries of health to identify and promote the implementation of evidence-based and cost-effective optimal therapy in the prescribing and use of proton ...
COMPUS Reports
March 15, 2007
The purpose of this report is to foster an understanding of how proton pump inhibitors (PPIs) are being prescribed and used in Canada. It is critical to have a clear picture of the current practice in Canada regarding PPIs so that gaps between the current practice and the optimal prescribing and use...
COMPUS Reports
March 15, 2007
Key Messages All PPIs are equally efficacious in the initial treatment of GERD, dyspepsia and other common GI conditions. Doubling the standard daily doses of PPIs, as initial therapy, is no better than standard daily dose therapy. PPIs are not efficacious in treating cough, asthma or laryngeal...
COMPUS Reports
March 1, 2007
The studies in the review suggest that combining educational multifaceted interventions that involve both professionals and patients with policy intervention may encourage appropriate prescribing and use of proton pump inhibitors. However, the decision on the selection of interventions should be tai...
COMPUS Reports
March 1, 2007
The purpose of this report is to identify gaps in the current prescribing and use of PPIs. This document presents three gaps in the use of PPIs as determined by a review of current practice in the prescribing and use of PPIs in Canada compared with the Evidence Statements contained in theScienti...
COMPUS Reports
March 1, 2007
The intent of this report is to identify a variety of interventions that would be best suited to optimizing the prescribing and use of proton pump inhibitors in different settings. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and ...
COMPUS Reports
March 1, 2007
This Executive Summary is based on a comprehensive Scientific Report (Optimal Therapy Report – COMPUS: Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease [Scientific Report]) and economic report on the topic, prepared by the Canadian Optimal Medication ...
COMPUS Reports
February 1, 2007
COMPUS Reports
February 1, 2007
COMPUS Reports
February 1, 2007